The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Genome-Wide Methylation Analyses in Glioblastoma Multiforme
Open accessAbstract
Few studies had investigated genome-wide methylation in glioblastoma multiforme (GBM). Our goals were to study differential methylation across the genome in gene promoters using an array-based method, as well as repetitive elements using surrogate global methylation markers. The discovery sample set for this study consisted of 54 GBM from Columbia University and Case Western Reserve University, and 24 brain controls from the New York Brain Bank. We assembled a validation dataset using methylation data of 162 TCGA GBM and 140 brain controls from dbGAP. HumanMethylation27 Analysis Bead-Chips (Illumina) were used to interrogate 26,486 informative CpG sites in both the discovery and validation datasets. Global methylation levels were assessed by analysis of L1 retrotransposon (LINE1), 5 methyl-deoxycytidine (5m-dC) and 5 hydroxylmethyl-deoxycytidine (5hm-dC) in the discovery dataset. We validated a total of 1548 CpG sites (1307 genes) that were differentially methylated in GBM compared to controls. There were more than twice as many hypomethylated genes as hypermethylated ones. Both the discovery and validation datasets found 5 tumor methylation classes. Pathway analyses showed that the top ten pathways in hypomethylated genes were all related to functions of innate and acquired immunities. Among hypermethylated pathways, transcriptional regulatory network in embryonic stem cells was the most significant. In the study of global methylation markers, 5m-dC level was the best discriminant among methylation classes, whereas in survival analyses, high level of LINE1 methylation was an independent, favorable prognostic factor in the discovery dataset. Based on a pathway approach, hypermethylation in genes that control stem cell differentiation were significant, poor prognostic factors of overall survival in both the discovery and validation datasets. Approaches that targeted these methylated genes may be a future therapeutic goal.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“BT142 G-CIMP status was confirmed by evaluating LINE methylation with the “Global DNA Methylation Assay – LINE-1″ kit (Active Motif), as described36, and by methylation-sensitive restriction digests.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [36]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A decade of exploring the cancer epigenome—biological and translational implications
Baylin, S. B., & Jones, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3130 · Cited by 2,871 · cited 2×
“Moreover, it appeared that the DNA demethylating agent, 5-deoxy-azacytidine (DAC) was able to reverse methylation and induce gene expression in cancer cells that were marked by both repressive chromatin marks (positive for H3K27me(3)) and methylation, but histone deacetylase inhibitor (HDACi) was not able to re-activa…”
BackgroundIdentification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337 · cited 5×
“Determination of Glioma CpG Island Methylator Phenotype (GCIMP) Status In both the discovery and validation datasets, we found those probes in the Illumina 27 K array that corresponded to the validated GCIMP markers as documented by Noushmehr et al [6].”
BackgroundMethodResultInfluentialControl of Developmental Regulators by Polycomb in Human Embryonic Stem Cells
Lee, T. I., Jenner, R. G., Boyer, L. A., Guenther, M. G., Levine, S. S., Kumar, R. M., Chevalier, B., Johnstone, S. E., Cole, M. F., Isono, K.-I., et al. (2006) · Cell · doi:10.1016/j.cell.2006.02.043 · Cited by 2,268 · cited 1×
“To quantify the degree of enrichment in our validated genes, we queried CHIP-seq datasets of H1-hESC (Tier 1) in ENCODE and from published papers [35,36].”
MethodRepetitive DNA and next-generation sequencing: computational challenges and solutions
Treangen, T. J., & Salzberg, S. L. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3117 · Cited by 1,597 · cited 1×
“Despite their abundance and importance in tumorigenesis, the sequences and maps of repetitive elements in the genome have been difficult to ascertain, because repeats created ambiguities in alignment and in genome assembly [13].”
BackgroundRepetitive Elements May Comprise Over Two-Thirds of the Human Genome
de Koning, A. P. J., Gu, W., Castoe, T. A., Batzer, M. A., & Pollock, D. D. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1002384 · Cited by 1,112 · cited 2×
“Repetitive elements may comprise over two-thirds of the human genome, and a high proportion of them are retrotransposons, whose expression is normally suppressed by methylation of cytosine [10].”
BackgroundIncreased methylation variation in epigenetic domains across cancer types
Hansen, K. D., Timp, W., Bravo, H. C., Sabunciyan, S., Langmead, B., McDonald, O. G., Wen, B., Wu, H., Liu, Y., Diep, D., et al. (2011) · Nature Genetics · doi:10.1038/ng.865 · Cited by 1,045
Hegi, M. E., Liu, L., Herman, J. G., Stupp, R., Wick, W., Weller, M., Mehta, M. P., & Gilbert, M. R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.5964 · Cited by 812 · cited 1×
“Nevertheless, in GBM, demethylating agents have not been considered in clinical trials because promoter MGMT methylation is related to temozolomide (TMZ) response [41].”
BackgroundAbundant quantitative trait loci exist for DNA methylation and gene expression in human brain
Gibbs, J. R., van der Brug, M. P., Hernandez, D. G., Traynor, B. J., Nalls, M. A., Lai, S.-L., Arepalli, S., Dillman, A., Rafferty, I. P., Troncoso, J., et al. (2010) · PLoS Genetics · doi:10.1371/journal.pgen.1000952 · Cited by 769 · cited 1×
“The methylation results using Illumina Methylation 27 K platform were published previously [22].”
MethodUncovering the role of 5-hydroxymethylcytosine in the epigenome
Branco, M. R., Ficz, G., & Reik, W. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3080 · Cited by 766 · cited 1×
“Although it is also a global methylation marker and is closely related to 5m-dC, 5hm-dC is enriched within the gene body, promoters and transcription start site, whereas 5m-dC and LINE1 were primarily located in heterochromatin and repetitive elements [43].”
BackgroundLandscape of Somatic Retrotransposition in Human Cancers
Lee, E., Iskow, R., Yang, L., Gokcumen, O., Haseley, P., Luquette, L. J., Lohr, J. G., Harris, C. C., Ding, L., Wilson, R. K., et al. (2012) · Science · doi:10.1126/science.1222077 · Cited by 762 · cited 1×
“This can lead to transposable elements insertion, and some of them, such as L1, can express their RNAs, which then promote DNA damage, spreading of methylation to promoters and genomic deletions [11,12].”
Background
Cited by
Insulator dysfunction and oncogene activation in IDH mutant gliomas
Flavahan, W. A., Drier, Y., Liau, B. B., Gillespie, S. M., Venteicher, A. S., Stemmer-Rachamimov, A. O., Suvà, M. L., & Bernstein, B. E. (2016) · Nature · doi:10.1038/nature16490 · Cited by 1,288
Circulating biomarkers for gliomas
Westphal, M., & Lamszus, K. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.171 · Cited by 181
Lee, W., Johnson, J., Gough, D. J., Donoghue, J. F., Cagnone, G., Vaghjiani, V., Brown, K. A., Johns, T. G., & John, J. C. S. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.34 · Cited by 141
“However, cancer cells, such as those giving rise to Glioblastoma multiforme, the most aggressive malignant primary brain tumour,(18,19) are extensively DNA methylated.(20) When induced to differentiate, they fail to increase mtDNA copy number and continue to express NESTIN, MUSASHI1 and CD133.”
BackgroundPark, A. K., Kim, P., Ballester, L. Y., Esquenazi, Y., & Zhao, Z. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy120 · Cited by 111
Brigliadori, G., Foca, F., Dall’Agata, M., Rengucci, C., Melegari, E., Cerasoli, S., Amadori, D., Calistri, D., & Faedi, M. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2116-y · Cited by 70
“Methylation status of each CpG island in the promoter region of many genes like MGMT have already been investigated [24] to evaluate their role in gene silencing.”
Background
Metadata
- Authors
- Lai, R. K., Chen, Y., Guan, X., Nousome, D., Sharma, C., Canoll, P., Bruce, J., Sloan, A. E., Cortes, E., Vonsattel, J.-P., Su, T., Delgado-Cruzata, L., Gurvich, I., Santella, R. M., Ostrom, Q., Lee, A., Gregersen, P., & Barnholtz-Sloan, J.
- Affiliations
- University of Southern California (US)
- Case Comprehensive Cancer Center (US)
- Columbia University (US)
- University Hospitals Cleveland Medical Center (US)
- Herbert Irving Comprehensive Cancer Center (US)
- North Shore University Hospital (US)
- Corresponding author
- Lai, Rose K.
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-02-21
- Volume
- 9
- Issue
- 2
- Pages
- e89376
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3931727
- OpenAlex
- W2036863866
- Cited by
- 54
- References
- 46
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 1 · 2023: 3 · 2022: 1 · 2021: 9 · 2020: 6 · 2019: 5 · 2018: 5 · 2017: 8 · 2016: 4 · 2015: 9
- FWCI
- 2.87
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- CUNY Academic Works (City University of New York) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Columbia Academic Commons (Columbia University)
- Funders
- National Institutes of Health
- National Cancer Institute (K07CA127468, R01CA139020, R01CA139020-27064, P30CA043703, P30CA014089)
- National Institute of Environmental Health Sciences (P30ES009089)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
- Keywords
- glioblastoma, DNA methylation, differentially methylated genes, promoter hypermethylation, promoter hypomethylation, LINE-1 retrotransposons, 5-methylcytosine, 5-hydroxymethylcytosine, immune pathways, stem cell differentiation, prognostic factors, overall survival, epigenetic therapy targets
- MeSH terms
- Adult, Aged, Aged, 80 and over, Brain, Brain Neoplasms, Female, Glioblastoma, Humans, Male, Middle Aged, Promoter Regions, Genetic, CpG Islands, DNA Methylation, Genome-Wide Association Study
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Genome-Wide Methylation Analyses in Glioblastoma Multiforme. https://app.cochat.ai/papers/10.1371/journal.pone.0089376
- The paper
- Lai, R. K., Chen, Y., Guan, X., Nousome, D., Sharma, C., Canoll, P., Bruce, J., Sloan, A. E., Cortes, E., Vonsattel, J.-P., Su, T., Delgado-Cruzata, L., Gurvich, I., Santella, R. M., Ostrom, Q., Lee, A., Gregersen, P., & Barnholtz-Sloan, J. (2014). Genome-Wide Methylation Analyses in Glioblastoma Multiforme. PLoS ONE. https://doi.org/10.1371/journal.pone.0089376
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.